Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome

Silvia Grassilli, Federica Brugnoli, Rossano Lattanzio, Marco Marchisio, Letizia Perracchio, Mauro Piantelli, Alberto Bavelloni, Silvano Capitani, Valeria Bertagnolo

Research output: Contribution to journalArticle

Abstract

Targeting different members of the Akt pathways is a promising therapeutic chance in solid tumors including breast cancer. The variable expression levels of Akt isoforms with opposite effects on tumor growth and metastasis, however, makes it difficult to select the inhibitors to be used for specific breast tumor subtypes. By using in vitro and in vivo models, we demonstrated here that Vav1, ectopically expressed in invasive breast tumors derived cells, down-modulates Akt acting at expression and/or activation levels depending on tumor subtype. The decreased p-Akt1 (Ser473) levels is a common effect of Vav1 up-modulation suggesting that, in breast tumor derived cells and independently of their phenotype, Vav1 interferes with signaling pathways ended to specifically recruit Akt1. Only in ER negative cell lines, the silencing of Vav1 induced the expression but not the activation of Akt2. A retrospective analysis of early invasive breast tumors allowed to establish the prognostic significance of the p-Akt/Vav1 relationship. In particular, low Vav1 levels negatively influence the follow-up of patients with low p-Akt in their primary tumors and subjected to adjuvant chemotherapy. As the use of specific or pan Akt inhibitors may not be sufficient or may even be detrimental, to increase the levels of Vav1 could be a new approach to improve breast cancer outcomes. This might be particularly relevant for tumors with a triple negative phenotype, for which target based therapies are not currently available.

Original languageEnglish
Pages (from-to)1012-1025
Number of pages14
JournalMolecular Oncology
Volume12
Issue number7
DOIs
Publication statusPublished - Jun 2018

Fingerprint

Breast Neoplasms
Neoplasms
Phenotype
Adjuvant Chemotherapy
Protein Isoforms
Neoplasm Metastasis
Cell Line
Therapeutics
Growth

Keywords

  • Akt1
  • Vav1
  • breast cancer

Cite this

Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome. / Grassilli, Silvia; Brugnoli, Federica; Lattanzio, Rossano; Marchisio, Marco; Perracchio, Letizia; Piantelli, Mauro; Bavelloni, Alberto; Capitani, Silvano; Bertagnolo, Valeria.

In: Molecular Oncology, Vol. 12, No. 7, 06.2018, p. 1012-1025.

Research output: Contribution to journalArticle

Grassilli, S, Brugnoli, F, Lattanzio, R, Marchisio, M, Perracchio, L, Piantelli, M, Bavelloni, A, Capitani, S & Bertagnolo, V 2018, 'Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome', Molecular Oncology, vol. 12, no. 7, pp. 1012-1025. https://doi.org/10.1002/1878-0261.12203
Grassilli, Silvia ; Brugnoli, Federica ; Lattanzio, Rossano ; Marchisio, Marco ; Perracchio, Letizia ; Piantelli, Mauro ; Bavelloni, Alberto ; Capitani, Silvano ; Bertagnolo, Valeria. / Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome. In: Molecular Oncology. 2018 ; Vol. 12, No. 7. pp. 1012-1025.
@article{e2f0183bd0404ec69804bb7da6a880cd,
title = "Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome",
abstract = "Targeting different members of the Akt pathways is a promising therapeutic chance in solid tumors including breast cancer. The variable expression levels of Akt isoforms with opposite effects on tumor growth and metastasis, however, makes it difficult to select the inhibitors to be used for specific breast tumor subtypes. By using in vitro and in vivo models, we demonstrated here that Vav1, ectopically expressed in invasive breast tumors derived cells, down-modulates Akt acting at expression and/or activation levels depending on tumor subtype. The decreased p-Akt1 (Ser473) levels is a common effect of Vav1 up-modulation suggesting that, in breast tumor derived cells and independently of their phenotype, Vav1 interferes with signaling pathways ended to specifically recruit Akt1. Only in ER negative cell lines, the silencing of Vav1 induced the expression but not the activation of Akt2. A retrospective analysis of early invasive breast tumors allowed to establish the prognostic significance of the p-Akt/Vav1 relationship. In particular, low Vav1 levels negatively influence the follow-up of patients with low p-Akt in their primary tumors and subjected to adjuvant chemotherapy. As the use of specific or pan Akt inhibitors may not be sufficient or may even be detrimental, to increase the levels of Vav1 could be a new approach to improve breast cancer outcomes. This might be particularly relevant for tumors with a triple negative phenotype, for which target based therapies are not currently available.",
keywords = "Akt1, Vav1, breast cancer",
author = "Silvia Grassilli and Federica Brugnoli and Rossano Lattanzio and Marco Marchisio and Letizia Perracchio and Mauro Piantelli and Alberto Bavelloni and Silvano Capitani and Valeria Bertagnolo",
note = "Molecular Oncology (2018) {\circledC} 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.",
year = "2018",
month = "6",
doi = "10.1002/1878-0261.12203",
language = "English",
volume = "12",
pages = "1012--1025",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome

AU - Grassilli, Silvia

AU - Brugnoli, Federica

AU - Lattanzio, Rossano

AU - Marchisio, Marco

AU - Perracchio, Letizia

AU - Piantelli, Mauro

AU - Bavelloni, Alberto

AU - Capitani, Silvano

AU - Bertagnolo, Valeria

N1 - Molecular Oncology (2018) © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

PY - 2018/6

Y1 - 2018/6

N2 - Targeting different members of the Akt pathways is a promising therapeutic chance in solid tumors including breast cancer. The variable expression levels of Akt isoforms with opposite effects on tumor growth and metastasis, however, makes it difficult to select the inhibitors to be used for specific breast tumor subtypes. By using in vitro and in vivo models, we demonstrated here that Vav1, ectopically expressed in invasive breast tumors derived cells, down-modulates Akt acting at expression and/or activation levels depending on tumor subtype. The decreased p-Akt1 (Ser473) levels is a common effect of Vav1 up-modulation suggesting that, in breast tumor derived cells and independently of their phenotype, Vav1 interferes with signaling pathways ended to specifically recruit Akt1. Only in ER negative cell lines, the silencing of Vav1 induced the expression but not the activation of Akt2. A retrospective analysis of early invasive breast tumors allowed to establish the prognostic significance of the p-Akt/Vav1 relationship. In particular, low Vav1 levels negatively influence the follow-up of patients with low p-Akt in their primary tumors and subjected to adjuvant chemotherapy. As the use of specific or pan Akt inhibitors may not be sufficient or may even be detrimental, to increase the levels of Vav1 could be a new approach to improve breast cancer outcomes. This might be particularly relevant for tumors with a triple negative phenotype, for which target based therapies are not currently available.

AB - Targeting different members of the Akt pathways is a promising therapeutic chance in solid tumors including breast cancer. The variable expression levels of Akt isoforms with opposite effects on tumor growth and metastasis, however, makes it difficult to select the inhibitors to be used for specific breast tumor subtypes. By using in vitro and in vivo models, we demonstrated here that Vav1, ectopically expressed in invasive breast tumors derived cells, down-modulates Akt acting at expression and/or activation levels depending on tumor subtype. The decreased p-Akt1 (Ser473) levels is a common effect of Vav1 up-modulation suggesting that, in breast tumor derived cells and independently of their phenotype, Vav1 interferes with signaling pathways ended to specifically recruit Akt1. Only in ER negative cell lines, the silencing of Vav1 induced the expression but not the activation of Akt2. A retrospective analysis of early invasive breast tumors allowed to establish the prognostic significance of the p-Akt/Vav1 relationship. In particular, low Vav1 levels negatively influence the follow-up of patients with low p-Akt in their primary tumors and subjected to adjuvant chemotherapy. As the use of specific or pan Akt inhibitors may not be sufficient or may even be detrimental, to increase the levels of Vav1 could be a new approach to improve breast cancer outcomes. This might be particularly relevant for tumors with a triple negative phenotype, for which target based therapies are not currently available.

KW - Akt1

KW - Vav1

KW - breast cancer

U2 - 10.1002/1878-0261.12203

DO - 10.1002/1878-0261.12203

M3 - Article

C2 - 29658179

VL - 12

SP - 1012

EP - 1025

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 7

ER -